|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 144.43 USD | +0.68% |
|
-0.42% | -20.92% |
| 10-14 | Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says | MT |
| 10-08 | RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 7.57B | - | ||||
| 1,263B | |||||
| 658B | |||||
| 521B | |||||
| 391B | |||||
| 369B |
Select your edition
All financial news and data tailored to specific country editions
